Skip to main content
. 2018 Nov 9;10(11):429. doi: 10.3390/cancers10110429

Figure 1.

Figure 1

Schematic representation and pharmacokinetics of CPX-351. (A) CPX-351 is a liposomal formulation of the cytotoxic drugs cytarabine and daunorubicin at a molar ratio of 1:5; (B) A comparison between the pharmacokinetic features of liposomal cytarabine and daunorubicin (on day 5 after infusion of CPX-351 (101 units/m2) [24]) versus non-liposomal forms [25,26,27].